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Abstract
It remains unknown whether newly identified anti-inflammatory/immunosuppressive cytokine interleukin-35 (IL-35) is
different from other anti-inflammatory cytokines such as IL-10 and transforming growth factor (TGF)-b in terms of inhibition
of inflammation initiation and suppression of full-blown inflammation. Using experimental database mining and statistical
analysis methods we developed, we examined the tissue expression profiles and regulatory mechanisms of IL-35 in
comparison to other anti-inflammatory cytokines. Our results suggest that in contrast to TGF-b, IL-35 is not constitutively
expressed in human tissues but it is inducible in response to inflammatory stimuli. We also provide structural evidence that
AU-rich element (ARE) binding proteins and microRNAs target IL-35 subunit transcripts, by which IL-35 may achieve non-
constitutive expression status. Furthermore, we propose a new system to categorize anti-inflammatory cytokines into two
groups: (1) the house-keeping cytokines, such as TGF-b, inhibit the initiation of inflammation whereas (2) the responsive
cytokines including IL-35 suppress inflammation in full-blown stage. Our in-depth analyses of molecular events that regulate
the production of IL-35 as well as the new categorization system of anti-inflammatory cytokines are important for the
design of new strategies of immune therapies.
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Introduction
In the past ten years, significant progress has been made in
characterizing the roles of CD4
+CD25
highFoxp3
+ regulatory T
cells (Tregs) in inhibition of various types of inflammation and
immunological diseases [1,2,3,4]. However, it remains poorly
defined what anti-inflammatory/immunosuppressive mechanisms
healthy individuals have in order to maintain normal tissue
functions such as by preventing the initiation of inflammatory
process and inhibiting the progression of inflammation.
CD4
+ T helper cells (Th) play essential roles in regulating
inflammation and immune responses via differentiation into
various Th functional subtypes, including Th1, Th2, Th17, Th9,
Th22, follicular Th, and Tregs [5]. The majority of Th cell
functions are fulfilled via the secretion of various cytokines, which
can play a dual role in regulating chronic inflammation and
autoimmune diseases [6]. Proinflammatory and Th1-related
cytokines such as IL-1 and IL-18 promote the development and
progression of inflammation and immune responses [7,8].
However, anti-inflammatory and Tregs-related cytokines such as
IL-10 and TGF-b exert clear anti-inflammatory activities [9]. It
therefore stands to reason that patients with autoimmune diseases
[10], angina [11], or familial hypercholesterolemia [12] have
lower serum IL-10 levels than healthy controls. In fact, the transfer
of human IL-10 or intracerebral injection of IL-10 significantly
inhibit experimental autoimmune encephalomyelitis [13,14].
These findings suggest that immunosuppressive/anti-inflammato-
ry cytokines play a critical role in the inhibition of inflammation
and autoimmune diseases.
Interestingly, IL-35 has been identified as a novel immunosup-
pressive/anti-inflammatory cytokine. It is a dimeric protein with
two subunits, IL-12A and Epstein-Barr virus induced 3 (EBI3)
[15,16]. Secretion of IL-35 has only been confirmed in non-
stimulated mouse Tregs [16] and in stimulated human Tregs [17]
but not detected in non-stimulated human Tregs [18]. In addition
to T cells, other cells in vessels, such as endothelial cells and
vascular smooth muscle cells, also generate various inflammation-
regulating cytokines [19]. However, the question of whether non-
T cells such as vascular cells express IL-35 remains.
Thus, despite significant progress, several important knowledge gaps
exist: First, how IL-35 is expressed in human and mouse tissues;
Second, if IL-35 is not constitutively expressed, then what are the
transcriptional and post-transcriptional mechanisms controlling its
induction and degradation; and Third, whether IL-35 is temporally
different from TGF-b and IL-10 in the inhibition of inflammation in
non-inflammatory or inflammatory stages. In this study, we hypoth-
esized that anti-inflammatory/immunosuppressive cytokines including
IL-35 have differential expression in various tissues under non-
stimulated conditions. Using database mining and statistical analysis
methods that we developed [20,21], we examined the expression of
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viewpoint. Furthermore, we examined the potential molecular
mechanisms regulating IL-35 expression. The in-depth analysis of
the expression patterns of IL-35 in comparison to that of other anti-
inflammatory cytokines could provide novel avenues for innovative
therapeutic treatments for inflammation and autoimmune diseases.
Methods
Tissue expression profiles of genes encoding anti-
inflammatory cytokines and their receptors
An experimental data mining strategy (Fig. 1), as we reported
[20,21], was used to analyze the expression profiles of mRNA
transcripts of genesin cardiovascular and other tissues in humans and
mice by mining experimentally verified human and mouse mRNA
expressions in the expressed sequence tag (EST) databases of the
National Institutes of Health (NIH)/National Center of Biotechnol-
ogy Information (NCBI) UniGene (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=unigene). Transcripts per million of genes of interest
were normalized with that of house-keeping b-actin in each given
tissue to calculate the arbitrary units of gene expression. A confidence
interval of the expression variation of house-keeping genes was
generated by calculating the mean plus two times that of the standard
deviation of the arbitrary units of three randomly selected house-
keeping genes (PRS27A, GADPH,and ARHGDIA in human; Ldha,
Nono,and Rpl32inmouse)normalized byb-actin in the given tissues
(Fig. 2A). If the expression variation of a given gene in the tissues was
larger than the upper limit of the confidence interval (the mean plus
two times the standard deviation) of the house-keeping genes, the
high expression levels of genes in the tissues were considered
statistically significant. Gene transcripts lower than one per million
were technically presented as no expression.
Analysis of transcription factor binding sites in the
promoters of anti-inflammatory cytokines
The promoter regions of targeted genes, defined as 1,500 bases
upstream of the transcription start site, were retrieved from the
NIH/NCBI Entrez Gene database (http://www.ncbi.nlm.nih.
gov/gene). In addition, the promoter region was analyzed with the
widely-used transcription factor database TESS (http://www.cbil.
upenn.edu/cgi-bin/tess/tess) to analyze the frequencies of 10
inflammation related transcription factor binding sites (Fig. 3A).
Alternative spliced isoforms of anti-inflammatory
cytokines
The presence and features of alternative promoters and
alternatively spliced isoforms of each gene were examined with
the AceView database of NIH/NCBI (http://www.ncbi.nlm.nih.
gov/IEB/Research/Acembly/index.html).
Correlation of the ratios of tissue SAH versus SAM
concentrations with the expression levels of anti-
inflammatory cytokines and receptors
The concentrations of S-adenosylmethionine (SAM) levels over
S-adenosylhomocysteine (SAH) levels were determined previously
by Ueland’s group [22] in tissues from adult male mice. Tissue
SAM/SAH ratios were used for further comparison and regression
analyses. Simple linear regression analyses were performed by
plotting mRNA levels of individual genes against the SAM/SAH
ratios in seven mouse tissues including the brain, kidney, liver,
spleen, heart, lung, and thymus. Multivariable regression analyses
were then performed to evaluate the effect of SAM/SAH ratios on
the expressions of anti-inflammatory cytokines and receptors [20].
Presence of adenine and uracil nucleotide-rich (AU-rich)
elements in 39-untranslated regions of anti-inflammatory
cytokines
The genes of interest were searched in the UTRdb (http://
utrdb.ba.itb.cnr.it/search) at the Institute for Biomedical Tech-
nologies, University of Bari for the existence of functional motifs
and signals in the 39-untranslated regions (39UTR) of each
mRNA. The presence of AU-rich elements in the 39UTRs was
searched using the AU-rich Element Containing mRNA Database
(ARED 3.0) (http://brp.kfshrc.edu.sa/ARED).
MicroRNA interactions with the mRNAs of anti-
inflammatory cytokines
The potential interactions of mRNAs from the genes of interest
with microRNAs were examined using the Bioinformatics and
Research Computing software TargetScan (http://www.targets-
can.org) from the Whitehead Institute for Biomedical Research in
the Massachusetts Institute of Technology (MIT). The significance
of MicroRNA binding to the genes of interest was determined
using the confidence intervals generated from the microRNAs
within Tarbase, an experimentally verified MicroRNA online
database (http://diana.cslab.ece.ntua.gr/tarbase). Briefly, human
microRNAs, which were single site effective and luciferase assay-
confirmed, were used to ensure that the interactions of the
microRNAs were specific to their respective mRNA targets. 27
microRNAs that met the criteria were selected and evaluated in
TargetScan to construct the intervals and set the lower limit for the
context values and score percentile as we reported [23].
MicroRNAs with the context score of 70% or higher and the
context value of 20.22 or lower were determined to be significant.
Figure 1. Flow chart of database mining strategy that was used
to generate tissue expression profiles of genes. NCBI: National
Center of Biotechnology Information; IDs: Identifications; EST: Expressed
sequence tag.
doi:10.1371/journal.pone.0033628.g001
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1. IL-35 is not constitutively expressed in non-stimulated
human tissues, whereas TGF-bs have high expression
levels
We hypothesized that to keep inflammation in check, various
tissues express certain levels of anti-inflammatory cytokines under
physiological conditions. To examine this hypothesis, a database
mining method we developed (Fig. 1) [21], was used to examine
experimentally verified expression profiles of mRNA transcripts of
anti-inflammatory cytokines (Table 1) and receptors (Table S1) in
NCBI-UniGene database. The expression of three sets of genes in
18 human tissues and 14 mouse tissues were examined (fewer
mouse tissues were examined due to the fact that gene expression
data for four of the mouse tissue counterparts were not available in
the database). The first set (Fig. 2B) had six anti-inflammatory
cytokines/cytokine subunits [IL-35 (IL-12A, EBI3), IL-10, three
isoforms of TGF-b (TGF-b1, TGF-b2, TGF-b3)]; the second set
(Fig. 2C) included two IL-35-related subunits (IL-12B, IL-27); and
the third set (Figure S1) included IL-35 receptor subunits (IL-
Figure 2. The gene expression profiles found in human and mouse tissues. A. Data presentation format (The data presented in X-, Y-axis,
and tissue order of ARHGDIA and Idha are applied to all the human and mouse genes examined respectively). As an example, the gene expression
profiles of human housekeeping gene Rho GDP dissociation inhibitor (GDI) alpha (ARHGDIA) in the eighteen tissues are presented, with the tissue
names and position numbers shown on the X-axis. The gene expression data were normalized by the b-actin (Hs. 520640) expression data from the
same tissue, which are presented on the left Y-axis. The expression ratios among tissues were generated by normalizing the arbitrary units of the
gene in the tissues with the median level of the arbitrary units of the gene in all the tissues which are presented on the right Y-axis. In order to define
confidence intervals for statistically higher expression levels of given genes, we calculated the confidence intervals of tissue expression for three
housekeeping genes [the mean X+26standard deviations (SD)=2.83] including ARHGDIA (Hs. 159161), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, Hs. 544577), and ribosomal protein S27a (RPS27A, Hs. 311640). The expression variations of given genes in tissues, when they were larger
than 2.83-fold, were defined as the high expression levels with statistical significance (the right Y-axis). To define confidence intervals for statistically
higher expression levels of given genes in 14 mouse tissues, we calculated the confidence intervals of tissue expression [the mean X+26standard
deviations (SD)=3.1] for three mouse house keeping genes including Lactate dehydrogenase A (Ldha, Mm. 29324), non-POU-domain-containing
octamer binding protein (Nono, Mm. 280069), and ribosomal protein L32 (Rpl32, Mm. 104368). The expression variations of given genes in tissues,
when they were larger than 3.1-fold, were defined as the high expression levels with statistical significance (the right Y-axis). B. The expression
profiles of suppressive cytokines in human (Left 2 columns, with cytokine members designated with capital letters) and mouse (right 2 columns, with
cytokine members designated with lowercase letters) tissues. C. The expression profiles of IL-35 related subunits in human and mouse tissue.
doi:10.1371/journal.pone.0033628.g002
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the transcription start site) of 3 housekeeping genes (ACTB, GAPDH, ARHGDIA), IL12A, EBI3, and TGFB1 were retrieved from the NIH/NCBI Entrez Gene
database, and were analyzed using TESS to determine the frequencies of 10 Transcription factors (TFs). The binding frequencies of the 10 TFs in the
promoter region of each gene were counted. Confidence interval was set by using the mean+26standard deviation (SD) of the TF binding
frequencies in the promoter of 3 housekeeping genes. The binding frequency which is higher than the uppermost confidence interval (p,0.05) is
considered significant.
doi:10.1371/journal.pone.0033628.g003
Table 1. The Unigene ID of human and mouse genes that were examined.
UniGene Name Cytokine/Receptor Subunit Related cytokine Unigene ID/Human Unigene ID/Mouse
Anti-inflammatory Cytokine
IL12A Interleukin 12 A IL35 Hs. 673 Mm.103783
EBI3 Epstein-Barr induced virus gene 3 IL35 Hs. 501452 Mm. 256798
IL10 Interleukin 10 IL10 Hs. 193717 Mm. 874
TGFB1 Transforming growth factor, beta 1 TGFb Hs. 645227 Mm. 248380
TGFB2 Transforming growth factor, beta 2 TGFb Hs. 133379 Mm. 18213
TGFB3 Transforming growth factor, beta 3 TGFb Hs. 592317 Mm. 3992
Other IL-35 related subunits
IL12B Interleukin 12 B IL12 Hs. 674 Mm. 239707
IL27 Interleukin 27 IL27 Hs. 582111 Mm. 222632
doi:10.1371/journal.pone.0033628.t001
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receptor (TGF-bR1, TGF-bR2). Of the 18 human tissues
examined (Table 2), the expression of the first IL-35 subunit, IL-
12A, was only found in brain, intestine, and spleen at very low
levels, whereas the second IL-35 subunit, EBI3, was expressed at
low levels in eye, lymph node, and pancreas, with high levels in the
placenta. IL-10 was also expressed at very low levels only in blood,
lung, and spleen but not in heart or vessels. In comparison, all
three isoforms of TGF-b were highly expressed in most tissues
including heart tissue. TGF-b1 was widely expressed in all tissues
except thymus, trachea, and vasculature, suggesting anti-inflam-
matory and other physiological functions of these cytokines in
human tissues. However, TGF-b2 was significantly expressed in
the trachea but not expressed in immune tissues (bone marrow,
lymph node, spleen, and thymus), and TGF-b3 was expressed
highly in heart but not in lymph node, spleen, and thymus,
suggesting that both TGF-b2 and TGF-b3 may be mainly
functional in non-immune tissues. In addition, the expression
patterns of anti-inflammatory cytokines in mouse tissues were
similar to their human counterparts except for IL-35 (IL-12A and
EBI3). IL-12A and EBI3 had significantly higher expression levels
in mice when compared to humans (Fig. 2B). Furthermore, IL-
12A was found in mouse blood, bone marrow, liver, and thymus,
whereas EBI3 was expressed in mouse blood, bone marrow, liver,
skin, spleen, thymus, and high levels in mouse lymph node. Taken
together, anti-inflammatory cytokines IL-35 and IL-10 had very
low expressions in non-stimulated tissues, whereas TGF-bs had
high expression levels, suggesting that the latter cytokines, but not
the former ones, are required for anti-inflammatory functions
under non-stimulated ‘‘house-keeping’’ conditions. This conclu-
sion is further supported by gene knockout studies in mice. The
gene deficiencies of IL-12A, EBI3, and IL-10 were not lethal to
mice in contrast to the massive inflammation leading to organ
failure and death observed in TGF-b1 knockout mice (Table 3).
IL-35 signals through heterodimeric receptor made of IL-
12Rb2 and gp130 (encoded by IL-6ST) or homodimers of each
chain [24]. IL-6ST was ubiquitously expressed in all the tissues
examined (Figure S1). Meanwhile IL-12Rb2 was expressed in
seven tissues but not in heart and vascular tissue. It is therefore
conceivable to speculate that the use of gp130-gp130 homodimers
may provide a mechanism by which IL-35 could affect tissues that
do not express IL-12Rb2.
Heart and vascular tissue expressed IL-10RA, IL-10RB, TGF-
bR1, and TGF-bR2 in human (Figure S1). Similarly, mouse heart
also expressed IL-10 and TGF-b receptor complexes. IL-10 acts
through a transmembrane receptor complex, which is composed
of IL-10RA and IL-10RB. It plays an important role in the control
of both innate and adaptive immunity [25]. IL-10 deficiency
promotes atherosclerotic lesion formation, characterized by
increased infiltration of inflammatory cells and increased produc-
tion of proinflammatory cytokines [26]. TGF-b isoforms including
TGF-b1, TGF-b2, and TGF-b3 were expressed in the vessel wall.
They signal through TGF-bR1 and TGF-bR2 via activating
Smad-dependent and Smad-independent signals and play a key
role in atherosclerosis [27]. These results suggest that cardiovas-
cular tissues express IL-10 and TGF-b receptors and are able to
accept these anti-inflammatory cytokine signals to inhibit inflam-
mation.
2. IL-35 is a responsive anti-inflammatory cytokine that
could be induced by proinflammatory cytokines in non-T
cells
As a new member of the IL-12 heterodimeric cytokine family,
IL-35 shares subunit IL-12A with IL-12 and subunit EBI3 with IL-
27. We classified the tissues into two tiers based on their expression
of the heterodimeric cytokine subunits (Table 4). Thus, tissues that
expressed both subunits of a given heterodimeric cytokine were
placed in the first tier of ‘‘ready to go’’ status. Tissues that did not
express one or both the subunits were placed in the second tier of
Table 2. Anti-inflammatory cytokines are differentially
expressed in human and mouse tissues.
Tissues Human Expression Mouse Expression
Adrenal GlandTGFB1, TGFB2
Blood IL10, TGFB1 Il12a, Ebi3, Il10, Tgfb3
Bone Marrow TGFB1, TGFB3 Il12a, Ebi3, Il10, Tgfb1, Tgfb3
Brain IL12A, TGFB1, TGFB2, TGFB3 Ebi3, Tgfb2, Tgfb3
Eye EBI3, TGFB1, TGFB2, TGFB3 Tgfb1, Tgfb2, Tgfb3
Heart TGFB1, TGFB2, TGFB3 Tgfb2, Tgfb3
Intestine IL12A, TGFB1, TGFB2, TGFB3 Ebi3, Tgfb1, Tgfb3
Kidney TGFB1, TGFB2, TGFB3 Tgfb2, Tgfb3
Liver TGFB1, TGFB2, TGFB3 Il12a, Ebi3, Tgfb1
Lung IL10, TGFB1, TGFB2, TGFB3 Ebi3, Tgfb1, Tgfb2, Tgfb3
Lymph Node EBI3, TGFB1 Ebi3
Pancreas EBI3, TGFB1, TGFB3 Tgfb1, Tgfb2, Tgfb3
Placenta EBI3, TGFB1, TGFB2, TGFB3
Skin TGFB1, TGFB2 Ebi3, Tgfb1, Tgfb2, Tgfb3
Spleen IL12A, IL10, TGFB1 Ebi3, Tgfb1, Tgfb3
Thymus - Il12a, Ebi3, Tgfb1, Tgfb2, Tgfb3
Trachea TGFB2
Vascular TGFB2
doi:10.1371/journal.pone.0033628.t002
Table 3. Effects of anti-inflammatory cytokine gene knockout (2/2) in mice.
Gene2/2 Viable Reported phenotype PMID
IL122/2 Yes Display normal development 8766560
EBI32/2 Yes No overt autoimmunity or inflammatory disease 12482940
IL102/2 Yes Only a local inflammation limited to the proximal colon 8402911
TGFB12/2 No Multifocal inflammatory cell response and tissue necrosis 1436033
TGFB22/2 No Perinatal mortality 9217007
TGFB32/2 No Die within 20 hours of birth 7493022
doi:10.1371/journal.pone.0033628.t003
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marrow, liver, and thymus tissues, but none of the human tissues,
were in the first tier. Since secretion of IL-35 has only been
confirmed in non-stimulated mouse Tregs [15] but not in non-
stimulated human Tregs [18], our results support the idea that the
expressions of IL-35 in tissues are different between human and
mouse. It should be noted, that it is unknown whether IL-35
expression in these four mouse tissues is due to potential high levels
of Tregs in these tissues. In addition, for the two other IL-35
related cytokines, IL-12 and IL-27, none of the human tissues were
in the first tier. For mouse IL-27, only lymph node was in the first
tier. While for mouse IL-12, bone marrow and thymus were in the
first tier. Taken together, the results suggest that IL-35 is not
constitutively expressed in human tissues but may be an inducible
anti-inflammatory cytokine that may control full-blown inflam-
mation.
We then hypothesized that IL-35 is upregulated in inflamma-
tion. The inducibility of IL-35 has been demonstrated in human
Tregs [17], and human conventional CD4
+Foxp3
2 T cells [28]
(Table 5). However, the inducibility of IL-35 in non-T cells
remains unknown. Since IL-35 nomenclature was first proposed in
2007, we analyzed the experimental reports published before
2007. We found that IL-12A and EBI3 can also be upregulated in
non-T cells including immature dendritic cells, epithelial cells,
smooth muscle cells, and vascular endothelial cells (Table 5). We
also found that IL-35 could be upregulated in human non-T cells,
such as microvascular endothelial cells, aortic smooth muscle cells,
and epithelial cells by stimulations with proinflammatory cytokines
tumor necrosis factor-a (TNF-a), interferon-c (IFN-c), and IL-1b
(Table 5). In addition, in epithelial cells, TNF-a induced the
upregulation of both IL-12A and EBI3 whereas type 1 T helper
cell (Th1) cytokine IFN-c only upregulated the expression of IL-
12A but not EBI3. TNF-a and IFN-c synergistically induced the
upregulation of IL-12A and EBI3 expression (Table 5). These
results suggest that the upregulation of IL-35 is double-gated and is
controlled by two different signals, and IL-35 is only upregulated
when the expressions of both subunits are induced. Moreover, in
one non-IL-35 study of bacterial infection-released endotoxin
lipopolysaccharide (LPS)-activated monocytes, IL-12A expression
rapidly increased, peaked at 12 hours and then dropped back to
background levels after 24 hours. In contrast, EBI3 showed
prolonged expression kinetics, although its transcription was
induced as early as 3 hours after LPS stimulation. Reaching
maximal EBI3 mRNA levels around 24 hours, EBI3 was still
above non-stimulated background levels after 72 hours (Table 6),
suggesting that IL-12A mRNAs are less stable than that of EBI3,
potentially because of mRNA degradation mechanisms. Since
EBI3 can dimerize with IL-12A to form IL-35 or dimerize with IL-
27 to form proinflammatory cytokine IL-27, and IL-12A can also
dimerize with IL-12B to form Th1 proinflammatory cytokine IL-
12, although we do not know the binding constants of these
dimerizations, we found that the upregulation time of IL-12 and
IL-27 were quantitatively earlier than that of IL-35 and that the
scales of IL-12 and IL-27 upregulation was higher than that of IL-
35. Once again, the analysis suggests that IL-35 is a responsive
cytokine that is induced by inflammation. Finally, we hypothesized
that if IL-35 and IL-10 are upregulated in response to
proinflammatory cytokine stimulation, the expression of ubiqui-
Table 4. The two-tier expression status of IL-35 and related cytokines is identified.
Cytokine Human tissue Mouse tissue
First tier (‘‘ready to go’’ expression status with two cytokine subunits)
IL-35 - Blood, Bone Marrow, Liver, Thymus
IL-12 - Bone Marrow, Thymus
IL-27 - Bone Marrow, Lymph Node
Second tier (‘‘inducible’’ expression status that requires up-regulation of at least one cytokine subunit)
IL-35 All the tissue Brain, Eye, Heart, Intestine, Kidney, Lung, Lymph Node, Pancreas, Skin, Spleen
IL-12 All the tissue Blood, Brain, Eye, Heart, Intestine, Kidney, Liver, Lung, Lymph Node, Pancreas, Skin, Spleen
IL-27 All the tissue Blood, Brain, Eye, Heart, Intestine, Kidney, Liver, Lung, Pancreas, Skin, Spleen, Thymus
doi:10.1371/journal.pone.0033628.t004
Table 5. IL-35 subunit mRNAs have been shown to be induced by stimulation in various human cell types.
IL-35 StudyPMID Cell Type Treatment Time Induction Fold
IL12A EBI3 b-Actin
Yes 20953201 Conventional CD4+Foxp3- T cells IL-35 9 day 60 18 -
Yes 21576509 Naı ¨ve regulatory T cells TCR/CD28 co-activation 9 day 100 150 -
No 17947455 Intestinal microvascular endothelial cells IL-1b 8 hour 20 10 1
No 15196212 Intestinal epithelial cell line TNF-a 8 hour 5 500 1
No 15196212 Intestinal epithelial cell line IFN-c 8 hour 35 1 1
No 15196212 Intestinal epithelial cell line TNF-a+IFN-c 8 hour 60 1000 1
No 19556516 Primary aortic smooth muscle cells TNF-a+IFN-c 24 hour 9 160 -
No 12446009 Immature dendritic cells CD40L+IFN-c 12 hour ‘ 23 -
doi:10.1371/journal.pone.0033628.t005
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stimuli. As expected, in another non-IL-35 report, we found that
proinflammatory cytokine IL-1b stimulation could upregulate IL-
35 and IL-10 but not TGF-b (Table 7). Taken together, these
results suggest that first, IL-35 and IL-10 are responsive anti-
inflammatory cytokines whereas TGF-bs is house-keeping anti-
inflammatory cytokines; second, in response to inflammation,
competition of dimerization of IL-35 against dimerization of IL12
and IL27 may be one of the novel mechanisms underlying IL-35’s
inhibition of inflammation; and third, due to the lower expression
levels, IL12A is quantitatively a limiting subunit for dimerization
and upregulation of cytokine IL-35, while EBI3 is not.
3. NF-kB transcription factor has high binding
frequencies in the promoter regions of IL-35 subunits IL-
12A and EBI3
The upregulation of IL-35 in response to proinflammatory
stimuli suggests that proinflammatory transcription factors may
mediate this upregulation. Thus, we hypothesized that IL-35
subunits IL-12A and EBI3 can be regulated by specific
proinflammatory transcription factors. To test this hypothesis,
the promoter sequences (1,500 bases upstream of the gene
transcription start site) from a control group of house-keeping
genes (ACTB, GAPDH, ARHGDIA) and the promoter sequences
of IL-35 subunits IL-12A, EBI3, and TGF-b1 were retrieved from
the NCBI database. The promoter regions were analyzed using
the transcription factor database TESS to examine the binding
frequencies of 10 inflammation-regulatory transcription factor
(TF) binding sites (Fig. 3B). Compared to the first control group,
the promoter regions of both IL-12A and EBI3 had significantly
higher frequencies of the binding sites for NF-kB (2 and 4 times
respectively) (Fig. 3C). In contrast, TGF-b1 had no binding sites
for NF-kB, which again supported its role as housekeeping anti-
inflammatory cytokine, which correlated with the results of non-
induction of TGF-b in response to NF-kB-mediated IL-1b
stimulation (Table 7). Our results are consistent with previous
reports on the roles of NF-kB in regulating IL-12A [29] and EBI3
[30] expression. In addition, we found that AP-1 and HSF-1
transcription factor had significantly high frequencies of binding
sites in the promoter region of IL-12A whereas GR and IRF-1 had
significantly high binding sites in the promoter region of EBI3.
These results may shed light on the differential induction of IL-35
subunits in response to proinflammatory cytokines (Table 5),
which correlates with the double-gated controls in upregulation of
these IL-35 subunits.
4. Alternative promoter and alternative splicing regulate
the structures, functions, and expressions of IL-35 and
other anti-inflammatory cytokines
Recent findings suggest that alternatively spliced isoforms of
cytokines may either enhance or antagonize the function of the
other isoforms of the cytokine [31]. Since IL-35 is not
constitutively expressed in most tissues, we searched for evidence
that IL-35 subunit genes have alternative promoters, which serves
as structural evidence for potential transcriptional induction of IL-
35 in response to different stimuli [32]. We hypothesized that IL-
35 and other anti-inflammatory cytokines have several alternative
spliced isoforms and promoters. To test this hypothesis, we
examined the AceView-NCBI database; the most comprehensive
database of alternative promoters and alternatively spliced gene
isoforms that is generated from experimental data of cDNA
sequence analysis from tissue mRNA transcriptomes [33]. As
shown in Table 8, all of the human anti-inflammatory cytokines
have numerous alternatively spliced isoforms. For example, IL-35
subunit IL-12A has six isoforms, whereas IL-35 subunit EBI3 has
two isoforms and two promoters (Fig. 4).
It should also be noted that one isoform of EBI3 was a secreted
form, while the other was a cellular form. The potential function of
intracellular isoform of EBI3 is not fully known, however in
addition to the interaction with IL-12A to constitute IL-35 and its
interaction with IL-27RA [34] to fulfill its cytokine function, EBI3
also interacts with four other proteins including Calnexin [35],
Golgi SNAP receptor complex member 1 [34], MyoD family
inhibitor [36], and SMAD family member 3 [36]. This may
Table 6. IL-35 subunit mRNAs have differential induction and duration of expression in human monocytes.
IL-35 Study PMID Cell Type Treatment Time (hour) IL12A (pg) EBI3 (pg) IL12B (pg) IL27 (pg)
No 12121660 Monocyte LPS 0 0 0 0 0
No 12121660 Monocyte LPS 3 5 50 5000 100
No 12121660 Monocyte LPS 6 50 90 10000 150
No 12121660 Monocyte LPS 12 100 180 24000 300
No 12121660 Monocyte LPS 24 10 400 2000 0
No 12121660 Monocyte LPS 48 0 180 1000 0
No 12121660 Monocyte LPS 72 0 140 0 0
doi:10.1371/journal.pone.0033628.t006
Table 7. Differential response of IL-35 subunits, IL-10, and TGF-b1 in response to proinflammatory cytokine IL-1b.
IL-35
Study PMID Cell Type Treatment Time Induction Fold
IL12A EBI3 IL10 TGFB1 b-Actin
No 15130917 Umbilical vein endothelial
cell
IL-1b 2.5 hour 2.2 6.1 2.3 0.9 1.0
doi:10.1371/journal.pone.0033628.t007
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has four secreted forms and two intracellular forms. Similarly, in
addition to its interactions with EBI3 to constitute IL-35 and its
interactions with IL-12B to constitute IL-12, IL-12A also interacts
with three other proteins; Wiskott-Aldrich syndrome protein
(WASP)-family member 1 [37], CD28 [38], and IL-8 [37], which
may provide insight for IL-12A intracellular and/or cytokine
functions. As we and others reported previously, a similar multi-
functional cytokine can be seen in translationally controlled tumor
protein (TCTP), which has an intracellular function of anti-
apoptosis [39] and a secreted cytokine function of histamine
release [40].
Ofnote,IL-35 subunitIL-12A,TGF-b2,and TGF-b3 havemore
than one secreted isoforms with isoform-specific protein sequences.
Potential binding differences of these secreted cytokine isoforms to
their receptors could lead to different functions. In addition, all of
anti-inflammatory cytokines have alternative promoters, suggesting
the importance of tissue-specific and/or stimulation-specific tran-
scriptional mechanisms in mediating the transcriptional upregula-
tion of the genes via alternative promoters [32]. Of note, there was
no alternative promoter data on IL-12A in the database. Future
work is needed to map out the detailed sequence requirements in
the alternative promoters in response to various stimuli.
5. Higher expression of IL-35 could be induced by higher
hypomethylation status in tissues
Previous reports showed that epigenetic mechanisms, including
methylation and demethylation, control T helper cell differenti-
ation and cytokine generation [41]. As we discussed in our recent
review [42], the ratio of cellular methylation donor S-adenosyl-
methionine (SAM) levels over S-adenosylhomocysteine (SAH)
levels is an important metabolic indicator of cellular methylation
status [43,44]. A higher SAM/SAH ratio suggests a higher
methylation status than normal (hypermethylation) whereas a
lower SAM/SAH ratio indicates a lower methylation status than
normal (hypomethylation). A previous report showed that feeding
rats with SAM, a methyl donor, inhibits the expression of TGF-
bR1 and TGF-bR2 [45], suggesting that intracellular global
methylation status regulates anti-inflammatory cytokine signaling.
We hypothesized that intracellular methylation/demethylation
status, a major metabolic stress-related epigenetic modification
[46], may regulate the expression of IL-35 and other anti-
inflammatory cytokines and the associated receptors in tissues. To
test this hypothesis, we used tissue concentrations of SAH and
SAM and the ratio of SAM over SAH in seven mouse tissues;
brain, heart, kidney, liver, lung, and thymus [20], which were
reported previously by Ueland’s group [22] (Fig. 5A). We
performed multivariable regression analyses to determine the
effect of cellular methylation, indicated by the SAM/SAH ratio,
on the expression of anti-inflammatory cytokines and receptors. As
shown in Figure 5B, the SAM/SAH ratios negatively correlated
with the expression levels of TGF-bR1 and TGF-bR2 (p,0.05).
This result corresponds with previous experimental studies [45],
which suggest that our approach was feasible in examining the role
of hypomethylation in regulating the expression of anti-inflam-
matory cytokines, and that DNA methylation status in cells can
determine the functional status of TGF-b signaling [47]. Notably,
the tissue expression of the two subunits of IL-35, IL-12a, and
EBI3, were increased as the tissue SAM/SAH ratios were
decreased (p=0.16 or 0.06). Although these P values were
.0.05, these results suggest that hypomethylation, induced by
metabolic stress including pro-atherogenic risk factor hyperhomo-
cysteinemia [20], could induce the expression of IL-35 in mice
(Fig. 5C). In support of our regression results, our analysis on
previously reported microarray experimental data in a non-IL-35
related study showed that treatment of human cells with
azacytidine (AZC), a DNA methyl transferase inhibitor and a
hypomethylation inducer, induces the upregulation of IL-35
subunit transcripts [48]. Similarly, since global DNA hypomethy-
lation has been observed in lupus, an autoimmune inflammatory
disease [49], taken together, our results suggest that DNA
hypomethylation-induced expression of IL-35 may result from a
negative feedback mechanism during full-blown inflammation.
6. The expressions of IL-35 can be regulated by an AU-
rich element-mediated mRNA degradation mechanism
Although IL-35 subunits can be induced by proinflammatory
cytokine in many cell types, their mRNAs have differential
Figure 4. Schematic presentation of how alternative promoter and alternative splicing regulate the expression of IL-35 subunit
Ebi3.
doi:10.1371/journal.pone.0033628.g004
Table 8. Alternative promoter and alternative splicing
regulate the expression and structures of anti-inflammatory
cytokines.
Gene Exons
Total
Isoforms
ORF
Isoforms Secreted Promoters
IL12A 7 6 6 4 -
EBI3 5 2 2 1 2
IL10 5 3 3 1 2
TGFB1 7 5 8 1 2
TGFB2 8 7 10 3 2
TGFB3 8 7 9 2 5
doi:10.1371/journal.pone.0033628.t008
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33628Figure 5. Higher hypomethylation status is positively associated with higher expression of IL-35 gene. A. Concentrations of SAM and
SAH in mouse tissues were previously examined by Ueland et al. B. Correlation of suppressive cytokines and TGF-b receptors with SAM/SAH ratios in
mouse tissues. C. Schematic presentation of how IL-35 may be regulated by methylation status. S-Adenosylhomocysteine (SAH) and S-
Adenosylmethionine (SAM) are intermediate metabolites of homocysteine-methionine metabolism cycle. SAH is a potent inhibitor of cellular
methylation. High SAM/SAH ratio is associated with hypermethylation of DNA and no IL12A/Ebi3 expression. Low SAM/SAH ratio is associated with
hypomethylation of DNA and Ebi3 can be expressed.
doi:10.1371/journal.pone.0033628.g005
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conditions (Table 6). We argued that non-constitutive expression
status of IL-35 in tissues may be realized by quick degradation
following their upregulation presumably via mRNA degradation
mechanisms. We hypothesized that RNA binding proteins may
regulate the mRNA stability of IL-35 subunits. Thus, we searched
for evidence for whether IL-35 subunit mRNA 39 untranslated
region (39UTR) had specific structural features mediating quick
degradation. Using a web-based AU-rich element mRNA
database [50], we analyzed all the mRNA 39untranslated regions
(UTRs) of anti-inflammatory cytokines in the UTR database
UTRdb (http:// utrdb.ba.itb.cnr.it/search). As shown in Table 9,
IL-12A and IL-10 contained AU-rich elements in their mRNA
39UTRs, suggesting that IL-35 (also IL-12) and IL-10 are under
regulation by the AU-rich element-mediated mRNA degradation
mechanism. In contrast, no AU-rich elements were found in
39UTRs of TGF-bs. Since our data showed that IL-12A is a
limiting factor for upregulation of IL-35 (Table 6), potential quick
degradation of IL-35 subunit IL-12A via an AU-rich mechanism
correlated with the non-constitutive expression status of IL-35
(Fig. 6). These suggest that AU-rich element-mediated mRNA
degradation may participate in regulating mRNA stability of IL-
35. Our results were supported by a previous experimental report
on the role of Tristetraprolin, an AU-rich element binding protein,
in regulating IL-12A (IL-35 subunit) expression [51].
7. The microRNAs that target IL-12A and EBI3 mRNA
39UTRs are not shared, suggesting that the expressions
of these two subunits of IL-35 may be regulated by
different microRNAs
MicroRNAs (MiRNAs or MiRs) are a newly characterized class
of short (18–24 nucleotide long) [52], endogenous, and non-coding
RNAs, which contribute to the development of particular disease
states through the regulation of diverse biological processes such as
cell growth, differentiation, proliferation, and apoptosis [53]. This
regulation occurs through base-pairing with messenger RNAs
(mRNAs) predominately at the 39UTR [54,55], and leads to
degradation or inhibition of mRNA translation [56]. A sequence
analysisidentifiedmiR-16aspossessing complementary sequenceto
the canonical AUUUA, which demonstrates a potential role for this
microRNA to modulate the stability of mRNAs with this AU-rich
element [57]. Since we found this AU-rich element in the 39UTR of
IL-35 subunit IL-12A and IL-10, we hypothesized that mRNAs of
IL-35 and other anti-inflammatory cytokines contain the structures
in their 39UTRs for microRNA binding and regulation. To
examine this hypothesis, we used the online microRNA target
prediction software, TargetScan (http://www.targetscan.org/)
developed in the Massachusetts Institutes of Technology. To ensure
that the predicted microRNAs have the binding quality equivalent
to that of experimentally verified microRNAs, we reasoned that
Figure 6. Positions of AUUA sequences in 39-UTR of IL-12A
mRNA are indicated.
doi:10.1371/journal.pone.0033628.g006
Table 9. 39-untranslated region in mRNA of anti-
inflammatory cytokines in human contain signals for RNA
protein binding.
Human Gene Length bp Signal Class Cluster
IL12A 460 ARE II 3
EBI3 579 - - -
IL10 1033 ARE I 5
TGFB1 728 - - -
TGFB2 6325 - - -
TGBF3 2150 - - -
doi:10.1371/journal.pone.0033628.t009
Figure 7. Schematic presentation of how miR-21 may regulate
the mRNA stability of IL-35 subunit IL12A.
doi:10.1371/journal.pone.0033628.g007
Table 10. Predicated microRNAs that could bind to anti-
inflammatory cytokines.
mRNA MicroRNA Position mRNA MicroRNA Position
IL12A miR-21 256–262 IL10 - -
miR-590-5p 256–262 TGFB1 miR-139-5p 292–298
EBI3 miR-576-5p 277–283 TGFB2 miR-141 109–115
miR-136 186–192 miR-200 A 109–115
miR-185 202–208 TGFB3 miR-631 772–778
miR-548m 211–217 miR-875-5p 960–966
miR-548m 217–223 miR-511 967–974
miR-128 251–257 miR-520d-5p 997–1003
miR-27b 252–258 miR-524-5p 997–1003
miR-27a 252–258 miR-876-3p 32–38
miR-552 317–323 miR-1291 365–371
miR-663b 388–394 miR-1291 452–458
miR-644 390–396 miR-649 486–492
miR-1303 409–415 miR-644 926–932
doi:10.1371/journal.pone.0033628.t010
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microRNAs and targeted 39UTRs of mRNAs that can be reflected
in the context value and context percentage. To test this hypothesis,
the confidence intervals for context value (the mean 626
SD=20.2560.12) and for context percentage (76.07619.07) were
generated, respectively, from 45 interactions between 27 experi-
mentally verified human microRNAs and 36 different genes (not
shown) within Tarbase, an online database of experimentally
verified microRNAs (http://diana.cslab.ece.ntua.gr/tarbase/) [58].
These human microRNAs were all confirmed using luciferase
reporter assays and had been found to effectively target a single
unique mRNA sequence. As shown in Table 10, microRNAs may
regulate anti-inflammatory cytokines. We found that 3 microRNAs
on the list have more than one binding site either within cognate
target 39UTR or within other genes. This finding correlated with
others’ report that somemicroRNAs have numerous mRNA targets
[59]. Of note, the microRNAs targeting IL-35 subunits IL-12A and
EBI3 mRNA 39UTRs were not shared, suggesting once again that
the expressions of these two subunits of IL-35 are differentially
regulated by different microRNAs in a ‘‘double-gated’’ manner.
Furthermore,2predictedmicroRNA targetincludingIL12Aonour
list have been confirmed in experiments (Table 11). These results
suggest that microRNAs may inhibit the mRNA stability and
translation of anti-inflammatory cytokines including IL-35 (Fig. 7),
either independently or via interactions with RNA binding protein
in various tissues.
Discussion
Since 2007, a new anti-inflammatory/immunosuppressive cyto-
kine, IL-35, has been defined [16,60,61]. Formed by heterodimer-
ization of Epstein-Barr virus-induced gene 3 (EBI3) protein with the
IL-12 p35 subunit (IL-12A) [15], IL-35 inhibits inflammation in
various autoimmunity models such as experimental colitis [16,62],
collagen-induced autoimmune arthritis [61], autoimmune demye-
lination in central nervous system [63], and type 2 T helper cell
(Th2)-mediated allergic asthma [64]. Although secretion of IL-35
has only been confirmed in Tregs [15], the contributions of IL-35
generated from tissues and cells other than T cells under non-
stimulated conditions remains poorly identified. In an effort to
bridge this knowledge gap we used a new experimental database
mining and statistical analysis technique to determine the tissue
expression of anti-inflammatory cytokines and receptors including
novel cytokine IL-35 and made the following findings: 1) anti-
inflammatory cytokines IL-35 and IL-10 are not constitutively
expressed in most tissues whereas TGF-bs have higher expression
levels in non-stimulated tissues; 2) IL-35 receptor subunit IL-6ST,
IL-10RA, IL-10RB, TGF-bR1, and TGF-bR2 receptor complex
are constitutively expressed in cardiovascular and other tissues; 3)
NF-kB transcription factor has higher binding frequencies in the
promoter region of IL-35 subunits; 4) alternative promoter and
alternative splicing regulate the structures and expressions of IL-35
and other anti-inflammatory cytokines and receptors; 5) higher
expression of IL-35 could be induced with higher hypomethylation
status. The higher binding frequencies of NF-kB-transcription
factor in IL-35 promoters, alternative promoters, along with higher
expression of IL-35 induced by hypomethylation all suggest that the
expression of IL-35 is inducible via several mechanisms. To support
our results, we also presented the reported experimental evidence
that IL-35 is indeed induced by stimulations of various proin-
flammatory cytokines and bacterial endotoxin LPS in vascular
endothelial cells, smooth muscle cells and monocytes; 6) the
expressions of IL-35 and IL-10 could be regulated by AU-rich
element-mediated mRNA degradation mechanism; and 7) the two
subunits of IL-35 are subjected to regulation by different
microRNAs. The last two structural evidences indicate that IL-35
Table 11. Some predicted MicroRNA targets listed above have been confirmed in experiments.
MicroRNA Reported Target Reported Function PMID
miR-21 IL35/IL12A Introduction of pre-miR-21 dose dependently inhibited cellular expression of
a reporter vector harboring the 39-untranslated region of IL-12p35.
19342679
miR-200A TGFB2 miR-200a downregulated the expression of TGF-b2 via direct interaction with
the its 39 untranslated region
20952520
doi:10.1371/journal.pone.0033628.t011
Figure 8. A new working model of responsive anti-inflammatory cytokine and housekeeping cytokine. Homeostatic tissues express
‘‘house-keeping’’ anti-inflammatory cytokines TGF-b1, TGF-b2, TGF-b3 to prevent it from initiation of inflammation. When tissues get inflamed,
proinflammatory factors may stimulate tissues to express ‘‘responsive’’ anti-inflammatory cytokines such as IL-35 by specific transcription factors to
counteract inflammation response. Furthermore, ARE binding proteins and MicroRNAs are responsible of the quick degradation of IL-35 mRNA
afterwards, by which IL-35 achieve non-constitutive expression status in tissues again.
doi:10.1371/journal.pone.0033628.g008
IL-35 Is a Responsive Anti-Inflammatory Cytokine
PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e33628can be degraded quickly by 39UTR-mediated mechanisms, which
correlates with the non-constitutive expression of IL-35 in tissues.
It is worth pointing out that the data retrieved from the
expression sequence tag (EST) database analyzed in this study is
more precise than that detected with traditional approaches
including Northern blot analysis and PCR analysis due to the un-
biased cDNA cloning and DNA sequencing procedures of EST
database deposits [21]. Thus, the expression patterns of IL-35,
other anti-inflammatory cytokines, and receptors are experimen-
tally-based and precise.
Transcription factors (TFs) are master genes which control the
expression of other genes. It is well-accepted that multiple binding
sites for a given TF within a promoter will increase the likelihood
of actual binding [65]. The most physiologically relevant TFs will
bind to the putative core promoter region (1,500 base pairs
upstream of the transcription start site) to fulfill their functions
[66]. Our strategy to identify TF binding profiles and transcrip-
tional signaling is an important advance in merging bioinformatics
and experimental science. This study, together with our previous
database mining work [20,21,23], utilized novel database mining
techniques to identify disease-related signaling pathways. Our
research method is featured as; (1) hypothesis-driven, (2)
intensively grounded in the literature, (3) panoramic and
integrative for gene and TF regulation, (4) based on the NCBI
experimental databases, (5) inclusive of well-characterized TFs in
the searchable database TESS; (6) statistically rigorous analysis of
available public databases, and (7) experimentally verified.
Alternative promoters play an important role in gene transcrip-
tion in response to tissue/cell-specific and stimulation-specific
transcription signaling [67]. One of the best examples of multiple
promoter usage is fibroblast growth factor-1 (FGF1) transcription,
which is controlled by at least four distinct promoters in a tissue-
specific manner. The 1.A and 1.B promoters of FGF1 are
constitutively active in their respective cell types. In contrast,
different biological response modifiers, including serum and
transforming growth factor-b, can induce the 1.C and 1.D
promoters of FGF1 [67]. Of note, our results showed that most
anti-inflammatory cytokines and cytokine receptors have more
than one promoter, suggesting the capacity of these genes to
respond to tissue-/cell-specific and stimulation-specific transcrip-
tion signaling [67]. Although endothelial cells and vascular smooth
muscle cells also generate various inflammation-regulating cyto-
kines [19], the lack of a cell type-specific gene expression database
prevents the analysis of databases in cell-specific manner. When
the detailed sequences become available, it will be possible to
compare the transcription factor binding profiles in the alternative
promoters of the same genes.
To summarize our results, we propose a new system of
categorizing anti-inflammatory cytokines (Fig. 8) based on the
following three criteria including (1) constitutive or non-constitu-
tive expression in tissues, (2) non-responsiveness or responsiveness
to proinflammatory stimuli, and (3) acceleration or no acceleration
of autoimmune and inflammation by cytokine gene deficiency. We
categorize anti-inflammatory cytokines into two groups: first, the
house-keeping cytokines are defined with constitutive expression in
tissues, non-responsiveness to proinflammatory stimuli, and
acceleration of autoimmune and inflammation in the absence of
the genes, such as TGF-bs; second, the definitions of responsive
cytokines include cytokines with non-constitutive expression in
tissues, responsiveness to proinflammatory stimuli and no
acceleration of autoimmune and inflammation in the absence of
the genes, including IL-35. IL-35 is not constitutively expressed in
most tissues similar to IL-10. Instead it is upregulated, by
hypomethylation and other proinflammatory signals, in human
tissues and most mouse tissues except mouse blood, bone marrow,
liver, and thymus. In addition, the expression and structure of IL-
35 are under various regulations including NF-kB transcription
factors, alternative promoter, alternative splicing, and mRNA
degradation via AU-rich-dependent and microRNA-dependent
mechanisms. These mechanisms underlie the upregulation and
quick degradation of IL-35. Our new working model and new
system in categorizing anti-inflammatory cytokines provide
important insight into the following two important issues: first,
how anti-inflammatory cytokines share their duties: the house-
keeping cytokines, such as TGF-bs, inhibit the initiation of
inflammation whereas the responsive cytokines including novel
cytokine IL-35 suppress full-blown inflammation; and second how
these two groups of anti-inflammatory cytokines orchestrate their
roles in suppressing inflammation in different stages in various
tissues and systems. Our findings are significant for future design of
novel anti-inflammatory/immunosuppressive therapies.
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